bezafibrate has been researched along with Complications of Diabetes Mellitus in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 6 (26.09) | 18.2507 |
| 2000's | 9 (39.13) | 29.6817 |
| 2010's | 3 (13.04) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abe, M; Fukuda, N; Haketa, A; Hatanaka, Y; Kobayashi, H; Nakamura, Y; Soma, M; Tanaka, S; Tsunemi, A; Ueno, T | 1 |
| Abe, K; Hirose, T; Taneyama, T; Teramoto, T | 1 |
| Kobayashi, J | 1 |
| Ishibashi, S | 1 |
| Ito, S; Kanno, T; Kobori, K; Kondo, A; Kotani, K; Maekawa, M; Manabe, M; Morita, H; Nakamura, H; Saito, K | 1 |
| Arcavi, L; Behar, S; Boyko, V; Caspi, A; Knobler, H; Reshef, N | 1 |
| Ahmed, MH; Osman, KA | 1 |
| Patel, J | 1 |
| Arai, N; Ebihara, K; Hosoda, K; Inada, Y; Ishii, T; Maruyama, K; Masuzaki, H; Nakano, S; Nakao, K; Shibata, N; Tanaka, T; Yamazaki, Y; Yasue, S | 1 |
| Rüth, E; Vollmar, J | 1 |
| Holler, HD; Janka, HU; Mehnert, H; Standl, A | 1 |
| Stratmann, FW | 1 |
| Hofmann, H; Holler, HD; Stratmann, FW | 1 |
| Bruneder, H; Klein, HJ | 1 |
| Barasch, E; Behar, S; Benderly, M; Caspi, A; Goldbourt, U; Graff, E; Pelled, B; Reicher-Reiss, H; Reisin, L; Roguin, N | 1 |
| Barradell, LB; Goa, KL; Plosker, GL | 1 |
| Beggs, PW; Clark, DW; Coulter, DM; Williams, SM | 1 |
| Bergemann, R; Brandt, A; Siegrist, W | 1 |
| Abdella, N; Akanji, AO; Mojiminiyi, OA | 1 |
| Tada, N | 1 |
| Betteridge, DJ | 1 |
| Noacco, C; Taboga, C; Tonutti, L | 1 |
| Chan, MK | 1 |
5 review(s) available for bezafibrate and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
[Guideline for management of lipid metabolism].
Topics: Bezafibrate; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Evidence-Based Medicine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Practice Guidelines as Topic; Primary Prevention; Risk; Simvastatin | 2002 |
Dyslipidaemia in diabetes.
Topics: Azetidines; Bezafibrate; Diabetes Complications; Diabetic Angiopathies; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Fish Oils; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Niacin | 2006 |
Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
Topics: Angina Pectoris; Apolipoproteins; Apolipoproteins A; Bezafibrate; Diabetes Complications; Drug Tolerance; Fibrinogen; Glucose; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Insulin Resistance; Lipoproteins; Male; Myocardial Infarction | 1996 |
[Overviews of fibrate].
Topics: Animals; Anticholesteremic Agents; Arteriosclerosis; Bezafibrate; Cholesterol, HDL; Cholesterol, LDL; Clofibrate; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Humans; Hyperlipidemias; Hypolipidemic Agents; Randomized Controlled Trials as Topic; Triglycerides | 2001 |
Lipid-lowering trials in diabetes.
Topics: Arteriosclerosis; Bezafibrate; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Humans; Lipoproteins, HDL; Lipoproteins, LDL; Male | 2001 |
5 trial(s) available for bezafibrate and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Influence of fibrate treatment on malondialdehyde-modified LDL concentration.
Topics: Adult; Aging; Apolipoproteins B; Arteriosclerosis; Bezafibrate; Diabetes Complications; Diabetes Mellitus; Enzyme-Linked Immunosorbent Assay; Female; Humans; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Sex Characteristics | 2004 |
High fasting glucose levels as a predictor of worse clinical outcome in patients with coronary artery disease: results from the Bezafibrate Infarction Prevention (BIP) study.
Topics: Aged; Bezafibrate; Blood Glucose; Coronary Disease; Diabetes Complications; Female; Glucose Intolerance; Glucose Tolerance Test; Humans; Hypolipidemic Agents; Male; Middle Aged; Multivariate Analysis; Myocardial Infarction; Prognosis; Proportional Hazards Models | 2004 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Glyburide; Humans; Hyperlipidemias; Hypolipidemic Agents; Middle Aged; Patient Compliance | 1982 |
[Treatment of hyperlipoproteinaemia in diabetic patients (author's transl)].
Topics: Adult; Aged; Bezafibrate; Blood Glucose; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Female; Humans; Hyperlipoproteinemias; Hypolipidemic Agents; Male; Middle Aged; Phospholipids; Placebos; Triglycerides | 1981 |
Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study.
Topics: Age Factors; Aged; Bezafibrate; Body Mass Index; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Female; Fibrinogen; Humans; Hypertension; Israel; Male; Middle Aged; Motor Activity; Multivariate Analysis; Myocardial Infarction; Risk Factors; Sex Factors; Smoking; Triglycerides | 1995 |
13 other study(ies) available for bezafibrate and Complications of Diabetes Mellitus
| Article | Year |
|---|---|
Lipoprotein Lipase Deficiency Arising in Type V Dyslipidemia.
Topics: Adult; Age of Onset; Bezafibrate; Diabetes Complications; Ezetimibe; Genetic Variation; Heterozygote; Humans; Hyperlipoproteinemia Type I; Hypertriglyceridemia; Hypolipidemic Agents; Insulin Resistance; Lipoprotein Lipase; Male | 2019 |
Determinants of Bezafibrate-induced Improvements in LDL Cholesterol in Dyslipidemic Patients with Diabetes.
Topics: Aged; Antihypertensive Agents; Bezafibrate; Blood Glucose; Cholesterol, LDL; Diabetes Complications; Dyslipidemias; Female; Humans; Hypoglycemic Agents; Logistic Models; Male; Middle Aged; Sex Factors | 2015 |
How Does Bezafibrate Affect the Plasma LDL Cholesterol Levels?
Topics: Bezafibrate; Cholesterol, LDL; Diabetes Complications; Dyslipidemias; Female; Humans; Male | 2015 |
Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
Topics: Antineoplastic Agents, Hormonal; Bezafibrate; Breast Neoplasms; Diabetes Complications; Disease Progression; Fatty Liver; Humans; Hypolipidemic Agents; Prognosis; Tamoxifen; Time Factors | 2006 |
Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; 3T3-L1 Cells; Adipocytes; Adiponectin; Adipose Tissue; Animals; Bezafibrate; Diabetes Complications; Diabetes Mellitus; Fatty Acids, Nonesterified; Hyperglycemia; Hypolipidemic Agents; Insulin Resistance; Liver; Male; Mice; Mice, Inbred Strains; Organ Size; Oxidoreductases; Peroxisome Proliferator-Activated Receptors; RNA, Messenger; RNA, Small Interfering; Triglycerides | 2007 |
[Improvement in diabetes control by treatment with bezafibrate].
Topics: Aged; Bezafibrate; Cholesterol; Clofibrate; Clofibric Acid; Diabetes Complications; Diabetes Mellitus; Female; Humans; Hyperlipidemias; Insulin; Male; Sulfonylurea Compounds; Triglycerides | 1982 |
[What are the possibilities in the treatment of primary hyperlipidemia in diabetes mellitus?].
Topics: Bezafibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents | 1982 |
[Effect of bezafibrate on the carbohydrate metabolism of 17 diabetics with hyperlipidemia].
Topics: Anticholesteremic Agents; Bezafibrate; Body Weight; Carbohydrate Metabolism; Clofibrate; Clofibric Acid; Diabetes Complications; Humans; Hyperlipidemias; Placebos | 1981 |
A comparison of the use, effectiveness and safety of bezafibrate, gemfibrozil and simvastatin in normal clinical practice using the New Zealand Intensive Medicines Monitoring Programme (IMMP).
Topics: Bezafibrate; Cohort Studies; Comorbidity; Diabetes Complications; Female; Gemfibrozil; Humans; Hypertension; Lipids; Male; Myocardial Ischemia; New Zealand; Practice Patterns, Physicians'; Product Surveillance, Postmarketing; Random Allocation; Retrospective Studies; Risk Factors; Simvastatin; Surveys and Questionnaires; Treatment Outcome | 1999 |
Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson).
Topics: Bezafibrate; Cost-Benefit Analysis; Diabetes Complications; Fenofibrate; Gemfibrozil; Humans; Hyperlipoproteinemia Type II; Hyperlipoproteinemia Type IV; Models, Econometric; Pyrazines; Treatment Outcome | 1993 |
Beneficial changes in serum apo A-1 and its ratio to apo B and HDL in stable hyperlipidaemic subjects after Ramadan fasting in Kuwait.
Topics: Adult; Apolipoprotein A-I; Apolipoproteins B; Bezafibrate; Body Weight; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Fasting; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Islam; Kuwait; Lipoproteins, HDL; Lovastatin; Male; Middle Aged | 2000 |
[Comparison of the efficacy of pantethine, acipimox, and bezafibrate on plasma lipids and index of cardiovascular risk in diabetics with dyslipidemia].
Topics: Bezafibrate; Cardiovascular Diseases; Diabetes Complications; Humans; Hyperlipidemias; Hypolipidemic Agents; Pantetheine; Pyrazines; Risk Factors | 1991 |
Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis.
Topics: Adolescent; Adult; Aged; Bezafibrate; Cholesterol, HDL; Coronary Disease; Delayed-Action Preparations; Diabetes Complications; Drug Evaluation; Female; Humans; Hypertriglyceridemia; Kidney Failure, Chronic; Lipids; Male; Middle Aged; Muscular Diseases; Peritoneal Dialysis, Continuous Ambulatory | 1990 |